Vivani Medical

Compare

785 Followers

VANI Stock Chart & Stats

$1.69

-$0.02(-1.59%)

At close: Jan 08 4:00 PM EST

$1.69

-$0.02(-1.59%)

Day’s Range― - ―

52-Week Range$0.91 - $1.88

Previous CloseN/A

Volume36.09K

Average Volume (3M)216.92K

Market Cap

$104.86M

Enterprise Value$88.25M

Total Cash (Recent Filing)$6.79M

Total Debt (Recent Filing)$18.62M

Price to Earnings (P/E)―

Beta1.11

Next Earnings

Nov 18, 2025

EPS Estimate

-0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding59,243,904

10 Day Avg. Volume237,036

30 Day Avg. Volume216,922

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)3.62

Price to Sales (P/S)0.00

P/FCF Ratio-2.99

Enterprise Value/Market Cap0.84

Enterprise Value/Revenue221.73

Enterprise Value/Gross Profit-5.88K

Enterprise Value/Ebitda-3.33

Forecast

1Y Price Target

$4.00

Price Target Upside136.69% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentVivani is planning for both studies in parallel with the Phase 1 expected to initiate and the Phase 2 to initiate shortly after Phase 1 completion.

Market OpportunityThere is a significant market opportunity with a 3-6 month semaglutide implant for weight loss.

Product DifferentiationNPM-139 is the only 6-month implant which provides significant differentiation as it eliminates the need for weekly injectables or daily orals.

Bears Say

Vivani Medical News

Vivani Medical withdraws record date for spin-off of Cortigent

Vivani Medical (VANI) announced that the Company will temporarily withdraw the previously announced record date for the planned...

28d ago

VANI

Vivani Medical Announces $15.7M Stock Offering

The latest update is out from Vivani Medical ( ($VANI) ). On October 26, 2025, Vivani Medical, Inc....

3d ago

VANI

Vivani Medical Delays Cortigent Spin-Off Record Date

Vivani Medical ( ($VANI) ) has issued an announcement. On October 3, 2025, Vivani Medical announced the temporary...

28d ago

VANI

Vivani Medical’s Strategic Focus and Innovative Product Development Drive Buy Rating

Naz Rahman, an analyst from Maxim Group, reiterated the Buy rating on Vivani Medical. The associated price target...

1M ago

VANI

Vivani Medical Announces Spin-Off of Cortigent

Vivani Medical ( ($VANI) ) has shared an announcement. On September 17, 2025, Vivani Medical announced the record...

1M ago

VANI

Vivani Medical announces spin-off of Cortigent subsidiary

Vivani Medical (VANI) announced that its board of directors has set the record date for the approved spin-off...

1M ago

VANI

Vivani Medical Shares Insights at Industry Conferences

Vivani Medical ( ($VANI) ) has provided an update. Vivani Medical, Inc. regularly updates the investment community through...

2M ago

VANI

Vivani Medical Announces Phase 1 Study for Semaglutide Implant

An announcement from Vivani Medical ( ($VANI) ) is now available. On September 4, 2025, Vivani Medical announced...

2M ago

VANI

Vivani Medical provides update on plans for NPM-139 semaglutide implant

Vivani Medical (VANI) announced plans to initiate a Phase 1 clinical study in the NPM-139 semaglutide implant program...

2M ago

VANI

Vivani Medical’s Promising Future: Buy Rating Backed by Financial Stability and Innovative Projects

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Vivani Medical, with...

2M ago

VANI

Vivani Medical’s Strategic Focus and Promising Developments Drive Buy Rating

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Vivani Medical and keeping the price target...

3M ago

VANI

Vivani Medical Reports Q2 2025 Results and $10M Financing

Vivani Medical, Inc. ( ($VANI) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

VANI

Vivani Medical Secures $10M Through Share Purchase Agreement

Vivani Medical ( ($VANI) ) has shared an update. On August 11, 2025, Vivani Medical entered into a...

3M ago

VANI

Vivani Medical reports results from LIBERATE-1 study of NPM-115

Vivani Medical (VANI) reported results from the LIBERATE-1 clinical study, the Phase 1 study of the exenatide GLP-1...

3M ago

VANI

VANI FAQ

What was Vivani Medical’s price range in the past 12 months?

Vivani Medical lowest stock price was $0.91 and its highest was $1.88 in the past 12 months.

What is Vivani Medical’s market cap?

Vivani Medical’s market cap is $104.86M.

When is Vivani Medical’s upcoming earnings report date?

Vivani Medical’s upcoming earnings report date is Nov 18, 2025 which is in 18 days.

How were Vivani Medical’s earnings last quarter?

Vivani Medical released its earnings results on Aug 13, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.1 by -$0.02.

Is Vivani Medical overvalued?

According to Wall Street analysts Vivani Medical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vivani Medical pay dividends?

Vivani Medical does not currently pay dividends.

What is Vivani Medical’s EPS estimate?

Vivani Medical’s EPS estimate is -0.11.

How many shares outstanding does Vivani Medical have?

Vivani Medical has 59,243,904 shares outstanding.

What happened to Vivani Medical’s price movement after its last earnings report?

Vivani Medical reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.1. Following the earnings report the stock price went up 0.794%.

Which hedge fund is a major shareholder of Vivani Medical?

Currently, no hedge funds are holding shares in VANI

Vivani Medical Stock Smart Score

Outperform

Fundamentals

Return on Equity

-177.75%

Trailing 12-Months

Asset Growth

-40.06%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vivani Medical

Vivani Medical (VANI) is a medical technology company specializing in the development of innovative implantable solutions for chronic disease management. The company operates in the healthcare sector, focusing on creating products that enhance patient outcomes and quality of life. Vivani Medical's core products include advanced drug delivery systems and neurostimulation devices that are designed to address various medical conditions.

Vivani Medical (VANI) Earnings & Revenues

Historic Earnings Reports

VANI Stock 12 Month Forecast

Average Price Target

$4.00

▲(136.69% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","1.25":"$1.25","2.5":"$2.5","3.75":"$3.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.25,2.5,3.75,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.3784615384615384,1.596923076923077,1.8153846153846152,2.0338461538461536,2.252307692307692,2.4707692307692306,2.689230769230769,2.9076923076923076,3.126153846153846,3.344615384615384,3.563076923076923,3.781538461538461,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.3784615384615384,1.596923076923077,1.8153846153846152,2.0338461538461536,2.252307692307692,2.4707692307692306,2.689230769230769,2.9076923076923076,3.126153846153846,3.344615384615384,3.563076923076923,3.781538461538461,{"y":4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.3784615384615384,1.596923076923077,1.8153846153846152,2.0338461538461536,2.252307692307692,2.4707692307692306,2.689230769230769,2.9076923076923076,3.126153846153846,3.344615384615384,3.563076923076923,3.781538461538461,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.66,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.21,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >